Contrast-enhanced Ultrasound Features of Intrahepatic Cholangiocarcinoma: A New Perspective

Tianjiao Chen1,5, Xiaoyan Chang2,5, Ke Lv1*, Yong Wang3, Xianshui Fu4, Li Tan1, Yang Gui1, Tongtong Zhou1, Xueqi Chen1 & Yuxin Jiang1

The objective of this study was to illustrate our specific findings for intrahepatic cholangiocarcinoma (ICC) lesions on contrast-enhanced ultrasound (CEUS). In this study, 21 patients at our hospitals with pathologically proven ICC and CEUS data were retrospectively enrolled. General clinical data of the patients, and features of lesions on conventional and contrast-enhanced ultrasound were recorded. Two experienced radiologists retrospectively reviewed all images by consensus. On gray-scale sonography, hypoechoic, isoechoic and hyperechoic lesions accounted for 85.7%, 9.5% and 4.8%, respectively, of all lesions. Hypovascular patterns were found for 95.2% of the lesions on color Doppler flow imaging. During the arterial phase of CEUS, heterogeneous hyperenhancement, homogeneous hyperenhancement, rim-like hyperenhancement, isoenhancement and hypoenhancement were observed for 61.9%, 19.0%, 9.5%, 4.8%, 4.8% of the lesions, respectively. During the portal venous and late phases, 85.7% and 95.2% of the lesions, respectively, exhibited hypoenhancement. In addition, 66.7% of the ICC lesions exhibited washed-out interiors but little decrease in enhancement at the periphery during the portal venous phase, resulting in the formation of a hyperenhanced peripheral rim. In conclusion, the rim sign in the portal venous phase of CEUS could help diagnose ICC. This trait could be related to the infiltrating growth pattern of ICC.

Intrahepatic cholangiocarcinoma (ICC) is a relatively rare type of primary liver cancer that arises from the intrahepatic bile duct epithelium1,2. However, the incidence and mortality of ICC are believed to have progressively increased over the past several decades3–7. The diagnosis of ICC plays an increasingly important role but remains highly challenging. In previous studies, certain researchers have suggested that peripheral rim-like enhancement during the arterial phase of contrast-enhanced ultrasound (CEUS) occurred in the majority of ICC lesions8–12. Whereas other results have indicated that this feature could be overestimated or based on a certain condition13–17. The issue of whether ICC has specific characteristics during CEUS examination remains controversial. In this study, we describe our specific findings for ICC on CEUS.

Methods

Patients. Between December 2004 and August 2019, 21 patients at our hospitals with pathologically proven ICC (verified via surgical specimen for 18 patients and via biopsy for 3 patients) and CEUS data were retrospectively enrolled in this study. Exclusion criteria included the presence of a combination of hepatocellular carcinoma and cholangiocarcinoma; uncertainty regarding whether lesions observed via CEUS matched the pathologically verified lesions; and the treatment of lesions prior to CEUS. Patients’ ages, symptoms and laboratory test results were recorded before therapy. Follow-up periods ranged from 0.5 to 87 months. The Institutional Review Board of

1Department of Ultrasound, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. 2Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. 3Department of Diagnostic Ultrasound, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, China. 4Department of Ultrasound, First Affiliated Hospital of PLA General Hospital, Beijing, 100048, China. *These authors contributed equally: Tianjiao Chen and Xiaoyan Chang. *email: lvke@163.com
Peking Union Medical College Hospital approved this retrospective study and waived the requirement for written informed consent.

**Contrast agent.** SonoVue® (Bracco, Italy), which is sulfur hexafluoride with a phospholipid shell, was used as the contrast agent. During CEUS examination, an intravenous bolus injection of SonoVue® at a dose of 2.4 ml was first administered, followed by a flush with 5 ml of normal saline.

**Conventional ultrasound and CEUS examinations.** Conventional ultrasound examination was performed first. Features of patients’ lesions, including location, number, size, echogenicity and vascularization, were observed and recorded during gray-scale and color Doppler sonography. After the target lesion had been confirmed, CEUS examination was performed using a low mechanical index (<0.1) technique. A timer was started when the contrast agent was injected. CEUS images were recorded for more than four minutes after contrast agent injection.

**Image analysis.** During CEUS examinations, the arterial, portal venous and late phases were defined as <30 s, 31–120 s and >120 s after contrast agent injection, respectively. Enhancement was classified as hyperenhancement, isoenhancement, or hypoenhancement relative to adjacent liver parenchyma. In accordance with various enhancement manifestations that were observed, enhancement patterns in the arterial phase were further categorized as homogeneous enhancement (uniform enhancement of the whole lesion), heterogeneous enhancement (different degrees of enhancement throughout the lesion), and peripheral rim-like enhancement (enhancement that was primarily limited to the periphery of the lesion). Two experienced radiologists retrospectively reviewed all images by consensus. Software QontraXt v.3.06 (Esaote, Italy) was used for quantitative analysis. One region of interest (ROI) was selected in the interior of the lesion, which showed rapid hyperenhancement during the arterial phase and decrease in enhancement during the portal venous phase. Another region of interest was selected at the periphery of the lesion which showed rapid hyperenhancement during the arterial phase and decrease in enhancement during the late phase. Then the parametric curves of the two ROIs were compared.

**Results**

**Patient characteristics.** There were 14 male patients and 7 female patients (mean age 58.3 ± 12.2 years; age range 33–83 years). ICC was discovered incidentally during physical examination in 12 patients. With respect to manifestations, 6 patients complained of abdominal discomfort; other symptoms included back pain, nausea and weakness. Positivity for hepatitis B surface antigen (HBsAg) was detected in 5 patients. 4 patients had elevated carbohydrate antigen (CA) 19-9 levels (41–17871 U/ml; 0–37 U/ml). Elevated alpha-fetoprotein (AFP) (112.6 ng/ml; 0–20 ng/ml) and carcinoembryonic antigen (CEA) (18.3 ng/ml; 0–5 ng/ml) levels were detected in only one patient respectively. Overall, 27.8% (5/18) of the patients experienced recurrence after surgical resection, and 33.3% (7/21) of the patients had died.

**Imaging findings.** Only one patient had two ICC lesions; the remaining patients had just one lesion. For the patient with two lesions, only the larger lesion was analyzed. Only 1 lesion was in the caudate lobe of the liver, whereas 8 lesions were in the right lobe, and 11 lesions were in the left lobe. There was another lesion located in the right lobe, left lobe as well as the caudate lobe of the liver. Among the 19 lesions that were histologically classified, 1 lesion was well differentiated; 1 lesion was well to moderately differentiated; 6 lesions were moderately differentiated; 5 lesions were moderately to poorly differentiated; and 6 lesions were poorly differentiated. The largest diameters of the ICC lesions ranged from 2.8 cm to 13.7 cm (mean, 5.3 ± 2.4 cm). On conventional ultrasound, 85.7% (18/21), 9.5% (2/21) and 4.8% (1/21) of the lesions were hypoechoic, isoechoic, and hyperechoic, respectively.

### Table 1. Conventional US Characteristics of 21 ICC Lesions.

| Echogenicity       | Arterial phase | Portal venous phase | Late phase |
|--------------------|----------------|---------------------|------------|
| Mean nodule size (cm) | 5.4 ± 2.6 | 4.4 ± 0.7 | 4.7 |
| Blood supply (n)   |                |                    |            |
| relatively abundant | 1              | 0                   | 0          |
| sparse or little    | 17             | 2                   | 1          |

### Table 2. CEUS Manifestations of 21 ICC Lesions.

| Enhancement Pattern          | Arterial phase | Portal venous phase With rim sign | Without rim sign | Late phase |
|------------------------------|----------------|----------------------------------|------------------|------------|
| Heterogeneous hyperenhancement (n) | 13              | 0                               | 0                | 0          |
| Homogeneous hyperenhancement (n) | 4               | 0                               | 0                | 0          |
| Rim-like hyperenhancement (n)  | 2               | 0                               | 0                | 0          |
| Isoenhancement (n)            | 1               | 1                               | 2                | 1          |
| Hypoenhancement (n)           | 1               | 13                              | 5                | 20         |
Figure 1. Intrahepatic cholangiocarcinoma (ICC) in a 62-year-old male. (see Supplementary Video S1). (a) Conventional ultrasound shows a hypoechoic lesion with a size of 4.2 cm × 3.5 cm in the left lobe of the liver (cursors); (b) Color Doppler sonography indicates a relatively sparse blood supply; (c) During the arterial phase (23 s), the lesion exhibits heterogeneous hyperenhancement; (d) During the portal venous phase (81 s), the lesion exhibits hyperenhancement of its interior with hyperenhancement in the peripheral region, resulting in the formation of a hyperenhanced rim; (e) During the late phase (186 s), the lesion exhibits hypoenhancement; (f) Micrograph (original magnification, ×100; hematoxylin and eosin stain) reveals that the periphery of the tumor is irregular and intermingled with the adjacent normal hepatic tissue. The lesion shows an infiltrative characteristic. (g) The parametric curves reveal perfusion of the region of interest in the interior (light green, Peak = 50.2, Sharpness = 0.074 1/s) and periphery (dark green, Peak = 53.1, Sharpness = 0.024 1/s) of the lesion from 10 s to 180 s.
and hyperechoic, respectively. Most of the lesions (95.2%, 20/21) exhibited sparse or little color Doppler signal (Table 1). Intrahepatic cholangiectasis was detected in 3 patients.

On CEUS, the most common enhancement pattern during the arterial phase was heterogeneous hyperenhancement, which was observed for 61.9% (13/21) of the lesions, followed by homogeneous hyperenhancement (19.0%, 4/21), rim-like hyperenhancement (9.5%, 2/21), isoenhancement (4.8%, 1/21) and hypoenhancement (4.8%, 1/21). During the portal venous phase, 85.7% (18/21) of the lesions exhibited hypoenhancement, and the remaining lesions exhibited isoenhancement. During the late phase, only 4.8% (1/21) of the lesions remained isoenhanced, whereas the remaining lesions were hypoenhanced (Table 2). All lesions showed decrease in enhancement during the portal venous and late phases, albeit to varying degrees. We also found a similar pattern for many lesions during the portal venous phase. In particular, these lesions exhibited washed-out interiors but little decrease in enhancement at the periphery. In other words, these lesions presented with hypoenhanced interiors but a hyperenhanced peripheral rim during the portal venous phase. During the late phase, this peripheral hyperenhancement gradually decreased until the entire lesion exhibited hypoenhancement. The aforementioned manifestations were observed for 66.7% (14/21) of the examined lesions (Figs. 1–3, see Supplementary Video S1–4).

Figure 2. Intrahepatic cholangiocarcinoma (ICC) in a 54-year-old male. (see Supplementary Video S2).
(a) Conventional ultrasound shows a hypoechoic lesion with a size of 4.5 cm × 3.6 cm near the hepatic hilar region (cursors); (b) Color Doppler sonography indicates a relatively abundant blood supply; (c) During the arterial phase (18 s), the lesion exhibits heterogeneous hyperenhancement; (d) During the portal venous phase (100 s), the lesion exhibits hypoenhancement of its interior with hyperenhancement in the peripheral region, resulting in the formation of a hyperenhanced rim; (e) During the late phase (321 s), the lesion exhibits hypoenhancement; (f) The parametric curves reveal perfusion of the region of interest in the interior (light green, Peak = 50.0, Sharpness = 0.105 1/s) and periphery (dark green, Peak = 56.8, Sharpness = 0.030 1/s) of the lesion from 10 s to 180 s.
Discussion

In our study, 66.7% of the ICC lesions exhibited a lasting hyperenhanced peripheral rim during the portal venous phase of CEUS. We called this character as the rim sign in the portal venous phase. These lesions exhibited washed-out interiors but little decrease in enhancement at the periphery during the portal venous phase, no matter what the enhancement pattern was during the arterial phase. Then a gradual decrease in enhancement occurred during the late phase (Fig. 4). This characteristic was different from the peripheral rim-like enhancement during the arterial phase mentioned in previous studies. To our knowledge, it had not been presented before and we thought that the features described above could aid in the differential diagnosis of ICC from hepatocellular carcinoma (HCC).

Cholangiocarcinoma is the second most common primary hepatic cancer and accounts for 10–20% of all primary hepatic tumors. ICC has been described as cholangiocarcinoma located proximally to the second-degree

Figure 3. Intrahepatic cholangiocarcinoma (ICC) in a 83–year-old male. (see Supplementary Video S3–4). (a) Conventional ultrasound shows a hypoechoic lesion with a size of 5.5 cm × 3.1 cm in the left lobe of the liver (arrow); (b) Color Doppler sonography indicates a relatively sparse blood supply; (c) During the arterial phase (22 s), the lesion exhibits peripheral rim-like enhancement; (d) During the portal venous phase (75 s), the lesion exhibits hypoenhancement of its interior with hyperenhancement in the peripheral region, resulting in the formation of a hyperenhanced rim; (e) During the late phase (219 s), the lesion and its surrounding area exhibit hypoenhancement; (f) The parametric curves reveal perfusion of the region of interest in the interior (light green, Peak = 38.5, Sharpness = 0.391 1/s) and periphery (dark green, Peak = 56.0, Sharpness = 0.075 1/s) of the lesion from 10 s to 112 s.
bile ducts. ICC accounts for less than 10% of cholangiocarcinoma cases. A meta-analysis has indicated that cirrhosis, chronic hepatitis B, chronic hepatitis C, alcohol use, obesity, and diabetes are major risk factors for ICC. Other suspected risk factors include biliary malformations such as primary sclerosing cholangitis, choledolithiasis, choledocholithiasis, hepatolithiasis, inflammatory bowel disease, choledochal cysts, smoking, and genetic polymorphisms.

ICC is typically asymptomatic and discovered incidentally via imaging examinations. ICC patients may also complain of abdominal pain or nonspecific symptoms such as fatigue, weakness, and weight loss. Several tumor markers may be elevated, but such markers do not exhibit high sensitivity or specificity for ICC. Elevated AFP levels are observed in only a small percentage of ICC patients. The sensitivities of CA19-9 and CEA for ICC are 50–63% and 15–68%, respectively. However, enhanced sensitivity and specificity can be achieved by utilizing a combination of both markers. Although various treatment options exist for ICC, complete surgical resection is traditionally the ideal therapeutic approach. However, few patients are candidates for this treatment.

With respect to ultrasound examination, in our study, ICC lesions were hypoechoic, isoechoic, or hyperechoic on gray-scale sonography; most of the examined lesions were hypoechoic. These findings were consistent with the results of some but not all previous investigations. Conventional ultrasound imaging findings for ICC are non-specific.

On CEUS, most lesions in our study showed hyperenhancement during the arterial phase, followed by wash-out to hypoenhancement during the portal venous phase. This characteristic was consistent with the features of most malignant tumors of the liver. We observed five enhancement patterns during the arterial phase, including heterogeneous hyperenhancement, homogeneous hyperenhancement, rim-like hyperenhancement, isoenhancement and hypoenhancement. In prior studies, certain authors have regarded lesions with peripheral rim-like hyperenhancement as the most common ICC lesions, although other researchers have found that lesions with this pattern were not observed in most ICC cases or were rarely present. In our study, most ICC lesions showed heterogeneous hyperenhancement during the arterial phase. However, it is reasonable whether heterogeneous hyperenhancement or peripheral rim-like hyperenhancement is observed for most ICC lesions, given that enhancement patterns of such lesions on CEUS may relate to tumor size and the distribution of tumor cells. Hyperenhanced areas in ICC lesions always correspond to regions with more tumor cells. Small ICC lesions tend to exhibit homogeneous enhancement, whereas larger ICC lesions tend to exhibit heterogeneous or peripheral enhancement. The likely cause of these findings is that tumor cells account for the majority in small ICC lesions, but that more fibrous tissues and necrosis appear as ICC lesions become larger. Certain authors have suggested that tumor size may also influence the washout patterns that are observed. More ICC lesions demonstrated early washout (<60 s) in a study by Li et al. (87.9%) than in a study by Vilana et al. (47.6%). Median tumor size was larger in the former study than in the latter study (4.0 cm vs 3.2 cm).

Guidelines from 2012 that were produced via the cooperative efforts of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB), the World Federation for Ultrasound in Medicine and Biology (WFUMB) and many other institutions suggest that ICC lesions have many enhancement patterns during the arterial phase but all exhibit washout during the late phase.

Figure 4. A sketch of the rim sign in the portal venous phase during CEUS examination. 66.7% of the ICC lesions in our study exhibited a lasting hyperenhanced peripheral rim during the portal venous phase of CEUS. These lesions exhibited washed-out interiors but little decrease in enhancement at the periphery during the portal venous phase, no matter what the enhancement pattern was during the arterial phase. Then a gradual decrease in enhancement occurred during the late phase.
during the portal venous phase and nonenhancement during the late phase24. In our study, all lesions showed decrease in enhancement during the portal venous and late phases, albeit to varying degrees. These findings were consistent with the common features of ICC described in the aforementioned guidelines. However, because the washout phenomenon of malignancies, this phenomenon is not particularly specific to ICC.

In our study, 66.7% of the lesions remained hyperenhanced at the periphery during the portal venous phase, resulting in the formation of a hyperenhanced peripheral rim. Subsequently, during the late phase, lesions with this enhancement pattern exhibited hypoenhancement in their interiors and gradually decreasing enhancement of the peripheral rim. We called it as the rim sign in the portal venous phase. To our knowledge, this perspective has not previously been reported.

In our opinion, the infiltrating growth pattern associated with ICC could be related to the formation of hyperenhanced peripheral rims during the portal venous phase. The peripheral region of ICC lesions is typically the transitional area between tumor tissue and normal hepatic tissue. For such lesions, washout could be slower for peripheral regions than for the lesion interiors. As for HCCs, cirrhosis is the major clinical risk factor2. And the lesion often has a fibrous pseudo-capsule in the presence of cirrhosis, which leads to a well-defined border7. Thus, the rim sign in the portal venous phase usually does not occur in HCCs and contributes to the differential diagnosis of ICC and HCC.

The features described above could aid in the differential diagnosis of ICC, such as by helping to distinguish ICC from HCC. However, ICC lesions behave somewhat similarly to metastases on CEUS examination; therefore, metastases should first be excluded. Nonetheless, more cases need to be studied.

During CEUS examination, 66.7% of the ICC lesions in our study showed a hyperenhanced peripheral rim during the portal venous phase, followed by gradually decreasing enhancement during the late phase. If a hepatic lesion shows characteristic of malignancy and this enhancement pattern on CEUS, ICC should be taken into consideration after metastases have been clinically excluded. The observed enhancement characteristics could be related to the infiltrating growth pattern of ICC.

Received: 10 July 2019; Accepted: 3 December 2019;
Published online: 18 December 2019

References
1. Padia, S. A. Intrahepatic Cholangiocarcinoma. Tech Vasc Interv Radiol. 18, 227–235 (2015).
2. Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. World Health Organization Classification of Tumours. WHO Classification of Tumours of the Digestive System (4th ed.). 205–224 (IARC Press, 2010).
3. Chung, Y. E. et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics. 29, 683–700 (2009).
4. Bridgewater, I. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 60, 1268–1289 (2014).
5. Malaguarnera, G. et al. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 34, 219–228 (2013).
6. Bartella, I. & Dafouti, J. F. Clinical Diagnosis and Staging of Intrahepatic Cholangiocarcinoma. J Gastrointestin Liver Dis. 24, 481–489 (2015).
7. Hammill, C. W. & Wong, L. L. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg. 207, 594–603 (2008).
8. Xu, H. X. et al. Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol. 85, 1029–1037 (2012).
9. Chen, L. D. et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol. 20, 743–753 (2010).
10. Guo, L. H. & Xu, H. X. Contrast-Enhanced Ultrasound in the Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Controversy over the ASASSLD Guideline. Biomed Res Int. 2015, 349172 (2015).
11. Xu, H. X. et al. Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. J Ultrasound. 34, 261–272 (2006).
12. Chen, L. D. et al. Enhancement patterns of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol. 81, 881–889 (2008).
13. Li, R. et al. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis. Abdom Imaging. 38, 112–119 (2013).
14. Galassi, M. et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int. 33, 771–779 (2013).
15. Böhle, W., Clemens, P. U., Heubach, T. & Zoller, W. G. Contrast-enhanced ultrasound (CEUS) for differentiating between hepatocellular and cholangiocellular carcinoma. Ultraschall Med. 33, E191–E195 (2012).
16. Vilana, R. et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology. 51, 2020–2029 (2010).
17. Xu, H. X. et al. Imaging of peripheral cholangiocarcinoma with low-mechanical index contrast-enhanced sonography and SonoVue: initial experience. J Ultrasound Med. 25, 23–33 (2006).
18. Brandi, G., Venturi, M., Pantaleo, M. A. & Ercolani, G. GICO. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. Dig Liver Dis. 48, 231–241 (2016).
19. Razumilava, N. & Gores, G. J. Cholangiocarcinoma. Lancet. 383, 2168–2179 (2014).
20. Palmer, W. C. & Patel, T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for hepatocellular cholangiocarcinoma. J Hepatol. 57, 69–76 (2012).
21. Dietrich, C. F., Cui, X. W., Boozari, B., Hocke, M. & Ignee, A. Contrast-enhanced ultrasound (CEUS) in the diagnostic algorithm of hepatocellular and cholangiocellular carcinoma, comments on the AASLD guidelines. Ultrasound Med. 33, S57–S66 (2012).
22. Li, C. et al. Value of contrast-enhanced sonography in the diagnosis of peripheral intrahepatic cholangiocarcinoma. J Clin Ultrasound. 39, 447–453 (2011).
23. Li, R. et al. Detailed analysis of temporal features on contrast enhanced ultrasound help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One. 9, e89612 (2014).
24. Claudon, M. et al. World Federation for Ultrasound in Medicine; European Federation of Societies for Ultrasound. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 39, 187–210 (2013).
Acknowledgements
This study was funded by the National Natural Science Foundation of China (No. 81873902); and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (No. 2016-I2M-3-005).

Author contributions
T.C. analyzed and interpreted study data; drafted the manuscript. X.Cha. collected, analyzed and interpreted study data. K.L. conceived and designed the study; analyzed and interpreted study data. Y.W. collected study data, contributed study materials and patients. X.F. collected study data, contributed study materials and patients. L.T. contributed study materials and patients. Y.G. contributed study materials and patients. T.Z. collected study data. X.Che. collected study data. Y.J. contributed study materials and patients. All authors edited and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-55857-6.

Correspondence and requests for materials should be addressed to K.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019